What makes a top CDMO partner for sterile injectables?

To be a top CDMO for sterile injectables, an aseptic manufacturer needs several specific and demanding qualifications. Here are some smart ways to evaluate potential partners across three key criteria: quality and compliance, technical capability, and supply reliability.

First and foremost, a robust quality system is non-negotiable. Every other CDMO capability is built on this foundation.

A manufacturer’s inspection track record is an especially important indicator of their quality sophistication. Sponsors should expect a sustained history of successful inspections by regulatory authorities across major markets — FDA, EMA member states, PMDA, and others — along with a high annual volume of customer audits.

Their underlying quality management system (QMS) also deserves close attention. A robust QMS operates as a single, integrated system across company sites and operations, rather than a patchwork of systems and SOPs across sites and departments. It should connect CAPA, deviation investigation, change control, SOP management, material status tracking, and audit management in one validated platform.

A top CDMO's regulatory affairs function should also play a key role in their quality system, supporting sponsors through registration in target markets, tracking the regulatory environment for emerging requirements, and adapting programs accordingly. Risk management should be proactive, integrated, and embedded in management oversight, not confined to the QA function alone.

For sterile injectables, technical depth is essential. To assess a CDMO’s capabilities, focus on four key areas:

Modalities and dosage forms. A top CDMO for injectables can handle the entire spectrum of services aseptic fill-finish requires, for both simple and complex formulations. Combination products, including prefilled syringes paired with autoinjectors or pen devices, also require integrated filling, assembly, and packaging processes — an increasingly vital capability as self-administration shifts from clinic to home.

Analytics and method lifecycle. Method development, qualification, and validation are often a key determining factor in manufacturing timelines — sometimes as much as the manufacturing process itself. A top CDMO offers in-house analytical development, ICH-aligned stability programs, and the laboratory capacity to support the entire product lifecycle, from  early-phase characterization to commercial release testing.

Digital and automation maturity. When you evaluate a CDMO’s digital infrastructure, it should be clear that they’ve kept pace with the last decade of evolution in aseptic manufacturing. Look for operational advances like robotic loading/unloading of lyophilizers, automated visual inspection, and continuous environmental monitoring, all of which reduce human interventions that historically increased aseptic risk profiles. A CDMO investing in these technologies signals a long-term commitment to protecting high-value products.

Packaging and device integration. A best-in-class CDMO should also support a comprehensive range of injection formats. Sponsors should expect support across container types — vials, cartridges, prefilled syringes — as well as closure systems, with the engineering capacity to manage device integration and final assembly.

Of course, a strong technical foundation is essential too. Look for a CDMO with a proven commitment to state-of-the-art infrastructure and equipment, advanced media systems, and cGMP-compliant standards across their business. Their team should have similar depth, with a comprehensive staff of engineers, scientists, and technicians that can support all dimensions of aseptic fill-finish.

Together, these capabilities allow a CDMO to carry a program from clinical development through commercial supply, with efficient, streamlined transitions at each stage of a product’s evolution.

Ultimately, capability without reliability is of limited use. The right CDMO partner should have resilient, comprehensive resourcing and logistic systems that are ready to support consistent global supply of your product.

Digital maturity is once again a key consideration: Consider how extensively they’ve adopted technology that streamlines logistics while protecting compliance and data integrity. To support that efficiency beyond their own walls, a world-class CDMO should have both broad and deep knowledge of global regulatory expectations, customs processes, and transport frameworks, all of which are essential to the efficient distribution of any batch.

Logistical versatility is equally important. A top CDMO can operate high-speed, resource-intensive filling lines for late-stage commercial volumes while also supporting small-volume clinical batches with frequent cleanroom changeovers. These two modes place very different demands on planning, scheduling, and personnel. A CDMO that does both well has typically made smart investments in physical assets, process design, and staff expertise.

Cold chain infrastructure rounds out the picture, especially now that many injectable biologics require qualified storage, handling, and shipping at 2–8°C or below. A top CDMO maintains the validated cold-chain infrastructure and traceability systems to support drug substance receipt, in-process holds, and finished-product distribution without temperature excursions.

Three key dimensions to consider when selecting a CDMO partner

The three key attributes — a sustained inspection record and integrated QMS, broad and deep technical capability across injectable modalities, and resilient, versatile supply infrastructure — are vital criteria for a sponsor seeking a top CDMO. At Vetter, we’ve built our organization around these attributes, and treat each as an ongoing investment, not a box checked one and forever.

Developing or commercializing a sterile injectable that needs this level of manufacturing partnership? Our team is always happy to review your specific requirements and outline how Vetter's capabilities align with your timeline and objectives. Contact Vetter to start the conversation.